

Focused 2012 Update of the CCS Guidelines for the Use of Antiplatelet Therapy

Disclosure of Conflict of Interests

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline					
	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Primary Panel						
Jean-Francis Tanguay	AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Roche, sanofi-aventis	None	Abbott Vascular, AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Roche	None	None	None
Shamir Mehta	AstraZeneca, Bayer, Bristol-Myers Squibb, sanofi-aventis	None	None	None	None	None
Margaret Ackman	None	Yes	None	None	None	None
Robert Bauer	None	None	None	Yes, Spartan Bioscience, details referred to original form	None	None
Alan Bell	AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, sanofi-aventis	None	AstraZeneca, Bayer, Boehringer Ingelheim, Pfizer, Daiichi Sankyo	None	None	None
Raymond Cartier	None	None	None	None	None	None
Wee Shian Chan	Leo Pharma	None	None	None	None	None
James Douketis	None	None	None	None	None	None
Andre Roussin	AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, Roche, sanofi-aventis, Schering Plough	None	Bayer, Bristol-Myers Squibb	None	None	None
Greg Schnell	AstraZeneca	None	None	None	None	None

Focused 2012 Update of the CCS Guidelines for the Use of Antiplatelet Therapy

Disclosure of Conflict of Interests

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline					
	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Subodh Verma	Abbott Vascular, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Lifesciences, Eli Lilly, Merck, Novartis, Pfizer, Roche, Servier, St. Jude Medical	Yes, Canadian Cardiovascular Research Network	Boehringer Ingelheim	None	None	None
Graham Wong	None	None	funding from UBC by AstraZeneca	None	None	None
Secondary Panel						
Paul W Armstrong	AstraZeneca, Eli Lilly, Merck	None	Boehringer Ingelheim, GlaxoSmithKline, Merck, Roche, sanofi-aventis, Ortho-Biotech	None	None	None
David Fitchett	Abbott Vascular, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, sanofi-aventis	None	None	None	None	None
Michael Love	None	None	None	None	None	None
Pierre Theroux	AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Merck, Schering Plough	None	AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Schering Plough	None	None	None
Robert Welsh	AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Roche, sanofi-aventis, Sepracor, CMPA	None	AstraZeneca, Boehringer Ingelheim, Roche, Portola, Johnson & Johnson	None	None	None